Show simple item record

dc.contributor.authorBista, Sudeep R
dc.contributor.authorHaywood, Alison
dc.contributor.authorHardy, Janet
dc.contributor.authorNorris, Ross
dc.contributor.authorHennig, Stefanie
dc.date.accessioned2019-03-11T01:44:54Z
dc.date.available2019-03-11T01:44:54Z
dc.date.issued2016
dc.identifier.issn0091-2700
dc.identifier.doi10.1002/jcph.641
dc.identifier.urihttp://hdl.handle.net/10072/99050
dc.description.abstractThis study aimed to describe exposure after fentanyl transdermal patch administration in patients with advanced cancer to quantify variability around the exposure. Patients (n = 56) with advanced cancer who received transdermal fentanyl (Durogesic®; median dose, 50 μg/h; range, 12–200 μg/h) provided venous blood samples (n = 163) at various times (0.5–72 hours) during several patch application intervals. Plasma fentanyl concentration was determined (median, 0.9 μg/L; range, 0.04–9.7 μg/L) by high‐performance liquid chromatography coupled to tandem mass spectrometry. Pharmacokinetic analysis was performed using nonlinear mixed‐effects modeling with NONMEM. A 1‐compartment distribution model with first‐order absorption and elimination described fentanyl exposure after transdermal patch administration. Fentanyl apparent clearance (between‐subject variability [BSV], %) was estimated at 122 L/h/70 kg and 38.5%, respectively. The absorption rate constant was 0.013 h−1. Between‐occasion variability on apparent clearance was 22.0%, which was lower than BSV, suggesting predictable exposure within the same patient and justifying therapeutic drug monitoring. Except for weight‐based dosing, no other patient characteristic could be identified to guide initial fentanyl dose selection in patients with advanced cancer.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherAmerican College of Clinical Pharmacology
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto9
dc.relation.ispartofjournalJournal of Clinical Pharmacology
dc.subject.fieldofresearchPharmaceutical Sciences
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode111504
dc.subject.fieldofresearchcode1115
dc.titleExposure to fentanyl after transdermal patch administration for cancer pain management
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Pharmacy
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version.
gro.hasfulltextNo Full Text
gro.griffith.authorHaywood, Alison
gro.griffith.authorNorris, Ross LG.
gro.griffith.authorBista, S R.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record